A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Aclidinium bromide (Primary) ; Aclidinium bromide/formoterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms AVANT
- Sponsors AstraZeneca
- 31 Dec 2018 Planned End Date changed from 19 Jul 2019 to 30 Jun 2020.
- 19 Apr 2018 Planned End Date changed from 29 Mar 2019 to 19 Jul 2019.
- 19 Apr 2018 Planned primary completion date changed from 29 Mar 2019 to 19 Jul 2019.